| AVY |
Report |
Q2 2026 adjusted EPS |
IN-LINE |
pred ~$2.49 vs. cons $2.47 |
MEDIUM |
| AVY |
Report |
Q2 2026 net sales |
IN-LINE |
pred ~$2.29B vs. cons $2.30B |
MEDIUM |
| AVY |
Report |
Q2 2026 organic sales growth |
MISS |
pred ~0.7% vs. cons 1.0% |
MEDIUM |
| AVY |
Guide |
Q3 2026 adjusted EPS |
LOWER |
guide ~$2.49 vs. cons $2.51 (Q3 2026) |
MEDIUM |
| AVY |
Guide |
FY2026 adjusted EPS |
LOWER |
guide ~$9.95 vs. cons $10.00 (FY2026) |
MEDIUM |
| AVY |
Guide |
Q3 2026 organic sales growth |
LOWER |
guide ~1.8% vs. cons 2.3% (Q3 2026) |
LOW |
| AVY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.2% |
— |
MEDIUM |
| AVY |
Return |
5-day cumulative residual |
-4.5% (FOLLOW-THROUGH) |
A near-consensus EPS result is likely to be outweighed by weaker organic growth and modestly lower Q3/FY2026 earnings implications; the out-period math should drive downward estimate revisions after the initial reaction. |
MEDIUM |